V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017255 | 160018267 | 1.78 | 62.3 | null | 2017-05-24 | 2017-05-25 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | ETOPOSIDE + IFOSFAMIDE | 100161502 |
| 160017258 | 160018268 | null | 73.6 | null | 2019-10-22 | 2019-10-25 | Rituximab | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100638043 |
| 160017260 | 160018269 | 1.75 | 78.6 | null | 2020-01-11 | 2020-02-22 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + DOXORUBICIN + VINCRISTINE | 01 | null | GEMCITABINE | 100969350 |
| 160017277 | 160018270 | 1.76 | 4.6 | null | 2021-09-08 | 2021-12-30 | Larotrectinib | 02 | null | NIRAPARIB | 100030899 |
| 160017287 | 160018271 | 0 | 114.6 | Palliative (P) | null | 2017-03-19 | CONFIRM TRIAL | 02 | N | DINUTUXIMAB BETA | 101651506 |
| 160017288 | 160018272 | 0 | 72 | Curative (C) | 2018-06-07 | 2019-01-16 | Cyclophosphamide + Vincristine | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100003501 |
| 160017297 | 160018273 | 0 | 14.4 | null | 2017-12-20 | 2019-11-11 | null | N | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101018565 |
| 160017314 | 160018274 | 1.64 | 63.3 | null | null | null | EW EuroEwing 2012 Arm B IE | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101633755 |
| 160017317 | 160018275 | null | null | null | 2020-06-28 | 2020-07-12 | VAI (Ifos 3g/m2) | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101618593 |
| 160017328 | 160018276 | 0 | 60.2 | Palliative (P) | 2020-03-28 | 2020-04-16 | Niraparib | 02 | N | NIRAPARIB | 101659424 |
| 160017330 | 160018277 | 1.88 | 114.6 | Palliative (P) | 2018-09-23 | 2018-09-25 | ETOP 13-18 BEAT-meso Trial | 02 | N | TRIAL | 101791368 |
| 160017335 | 160018279 | null | 57 | Palliative (P) | 2019-04-21 | 2019-05-20 | Dacarbazine | 02 | N | VAI | 100789822 |
| 160017358 | 160018280 | 1.69 | 59.5 | Palliative (P) | 2016-09-20 | 2017-08-07 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | EW EUROEWING 2012 ARM A VAC | 100480278 |
| 160017360 | 160018281 | 1.66 | 85.7 | null | 2017-03-14 | 2017-04-09 | CONFIRM TRIAL | N | null | ETOP 13-18 BEAT-MESO TRIAL | 100725871 |
| 160017362 | 160018282 | 1.76 | 71.4 | Palliative (P) | 2018-02-16 | 2018-12-29 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CAV | 101168777 |
| 160017370 | 160018283 | 1.63 | 81 | Palliative (P) | 2018-10-25 | 2018-10-25 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | N | IPM | 100721352 |
| 160017375 | 160018284 | 1.64 | 94.8 | null | 2019-06-11 | 2020-02-01 | Rituximab | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101613656 |
| 160017378 | 160018285 | 1.52 | 65.15 | Palliative (P) | 2016-06-16 | 2016-07-05 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100810764 |
| 160017385 | 160018286 | 1.95 | null | Palliative (P) | 2018-07-14 | 2018-07-18 | Ifosfamide + Liposomal Doxorubicin | 02 | N | CAPECITABINE + OXALIPLATIN | 100674697 |
| 160017388 | 160018287 | 1.6 | 98.1 | Curative (C) | 2019-10-16 | 2020-02-21 | Cyclophosphamide + Vincristine | 02 | N | NB HRNBL-1 BUMEL MAT | 101109548 |
| 160017390 | 160018288 | 0 | 10.4 | Curative (C) | 2019-09-05 | 2019-11-23 | Trastuzumab Subcutaneous | 02 | N | LENVATINIB | 100851729 |
| 160017396 | 160018289 | 0 | 19 | Curative (C) | 2020-01-11 | 2020-01-11 | LANREOTIDE | 02 | N | NOT MATCHED | 101280426 |
| 160017398 | 160018290 | 1.82 | 90.6 | null | 2020-09-17 | 2021-02-15 | NB HRNBL-1 COJEC Ind COURSE B | null | null | DOXORUBICIN + IFOSFAMIDE | 100262428 |
| 160017418 | 160018291 | 1.64 | 81.6 | null | 2020-05-11 | 2020-11-02 | null | 02 | null | NOT MATCHED | 100627889 |
| 160017419 | 160018292 | 1.72 | 49 | Curative (C) | 2015-08-02 | 2016-07-13 | EW EuroEwing 2012 Arm B IE | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100343892 |
| 160017422 | 160018293 | 0 | 69.5 | null | 2020-03-25 | 2020-04-13 | EW EuroEwing 2012 Arm B VC | 2 | null | IFOSFAMIDE | 100534873 |
| 160017429 | 160018294 | 0 | 48.9 | null | 2019-04-26 | 2019-09-05 | AFATINIB | 02 | null | TRIAL | 101753260 |
| 160017434 | 160018295 | null | null | Curative (C) | 2021-08-28 | 2021-09-11 | Cyclophosphamide + Vincristine | 02 | N | DACARBAZINE | 100288250 |
| 160017444 | 160018297 | 1.65 | 83.5 | null | 2020-10-02 | 2020-11-20 | Pemetrexed | 02 | null | CISPLATIN | 100126331 |
| 160017454 | 160018298 | 1.56 | 98 | Curative (C) | 2017-03-26 | 2017-04-03 | ETOP 13-18 BEAT-meso Trial | N | N | VINCRISTINE | 100695137 |
| 160017457 | 160018299 | 0 | 74.5 | Palliative (P) | 2018-07-18 | 2019-05-09 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | DARATUMUMAB | 100866679 |
| 160017458 | 160018300 | null | 73.2 | Curative (C) | 2019-05-23 | 2019-06-08 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | N | TRIAL | 100059797 |
| 160017462 | 160018301 | 0 | 74.6 | null | 2020-01-26 | 2020-02-04 | Rucaparib | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100297998 |
| 160017464 | 160018302 | 1.06 | 72.5 | Palliative (P) | 2018-05-17 | 2018-06-14 | GEMCITABINE | 2 | N | NIRAPARIB | 101623145 |
| 160017466 | 160018303 | 1.6 | 80 | Neo-adjuvant (N) | 2017-10-17 | 2017-10-20 | CONFIRM TRIAL | 02 | N | PEMETREXED | 101683920 |
| 160017473 | 160018304 | 1.83 | 74.7 | Neo-adjuvant (N) | 2018-06-02 | 2018-12-23 | Trial Unspecified | 02 | N | DACARBAZINE + DOXORUBICIN | 101144339 |
| 160017476 | 160018305 | 1.82 | 57.8 | Palliative (P) | 2018-01-27 | 2018-02-13 | NB HRNBL-1 Isotretinoin | 02 | null | CISPLATIN + ETOPOSIDE | 101680592 |
| 160017480 | 160018306 | 0 | 104 | Palliative (P) | null | null | null | null | null | ABIRATERONE | 100968982 |
| 160017488 | 160018307 | 1.65 | 72.5 | null | 2018-08-03 | 2018-08-20 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | CARBOPLATIN + VINORELBINE | 101263396 |
| 160017490 | 160018308 | 1.58 | 72.8 | null | 2017-10-18 | 2019-03-17 | EW EuroEwing 2012 Arm B IE | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100770715 |
| 160017495 | 160018309 | 1.81 | 95.4 | Palliative (P) | 2018-07-05 | 2018-08-14 | Pemetrexed | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100568199 |
| 160017502 | 160018310 | 1.7 | 64.4 | null | 2019-05-07 | 2019-11-25 | NB HRNBL-1 TVD | 02 | null | CONFIRM TRIAL | 101525945 |
| 160017546 | 160018311 | 1.69 | 18 | Curative (C) | 2019-11-27 | 2019-12-04 | Doxorubicin + Ifosfamide | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100868010 |
| 160017548 | 160018312 | 1.82 | 89.1 | Palliative (P) | 2016-07-28 | 2016-09-29 | Irinotecan + Temozolomide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100915208 |
| 160017554 | 160018313 | 1.7 | 79.3 | null | 2020-05-31 | 2020-06-14 | Olaparib | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101244428 |
| 160017556 | 160018314 | 1.8 | 61.9 | Curative (C) | 2021-12-19 | 2021-12-20 | NB HRNBL-1 COJEC Ind COURSE C | 02 | Y | CYCLOPHOSPHAMIDE | 101502820 |
| 160017558 | 160018315 | 0 | 11.2 | Curative (C) | 2019-10-21 | 2019-12-03 | Trial Unspecified | N | N | EURO-EWING | 101162573 |
| 160017563 | 160018316 | 1.63 | 115.8 | Curative (C) | 2021-01-10 | 2021-01-17 | Niraparib | 02 | null | CYCLOPHOSPHAMIDE | 100927757 |
| 160017571 | 160018317 | 1.65 | 63.9 | null | 2019-06-24 | 2019-07-27 | IPM | 02 | null | MESO-02 TRIAL | 101033478 |
| 160017573 | 160018318 | 1.61 | 13.4 | Curative (C) | 2016-06-10 | 2016-06-17 | Rucaparib | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100093601 |